medications Archives - BCDiabetes British Columbia Diabetes Care, Research, and Education Tue, 28 May 2019 18:26:30 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://www.bcdiabetes.ca/wp-content/uploads/2018/04/favicon-150x150.png medications Archives - BCDiabetes 32 32 BC Pharmacare to cover SGLT-2 inhibitors and to delist the Lantus brand of insulin glargine U100 https://www.bcdiabetes.ca/bc-pharmacare-sglt-2-inhibitors-and-lantus-brand-of-insulin/ Tue, 28 May 2019 17:30:22 +0000 https://www.bcdiabetes.ca/?p=2572 Yesterday BC Minister of Health Adrian Dix announced Pharmacare coverage of the SGLT-2 inhibitor class represented by empagliflozin (Jardiance). Although BCDiabetes would have preferred that all three SGLT2 inhibitors on the Canadian market be covered, the long overdue announcement was most welcome news. Our readers will be aware of the long-running BCDiabetes advocacy campaign for […]

The post BC Pharmacare to cover SGLT-2 inhibitors and to delist the Lantus brand of insulin glargine U100 appeared first on BCDiabetes.

]]> Statins for all? https://www.bcdiabetes.ca/statins-for-all/ Thu, 07 Feb 2019 18:38:06 +0000 https://www.bcdiabetes.ca/?p=2496 On February 1, 2019, the prestigious medical journal the Lancet published a meta-analysis examining potential benefits the statin and class of medication. The article confirmed and extended the powerful evidence for benefit for the use of statins in people with a previous history of heart disease, stroke and for those with diabetes.  It showed that […]

The post Statins for all? appeared first on BCDiabetes.

]]> Third SGLT2 inhibitor to be marketed in Canada https://www.bcdiabetes.ca/third-sglt2-inhibitor-in-canada/ https://www.bcdiabetes.ca/third-sglt2-inhibitor-in-canada/#comments Mon, 05 Oct 2015 17:08:05 +0000 https://www.bcdiabetes.ca/?p=828 Empagliflozin “Jardiance” is the third member of the SGLT2 inhibitor class to be marketed in Canada.  Like the other two members of the class (canagliflozin “Invokana” and dapagliflozin “Forxiga”) it lowers blood sugar and weight by causing wasting of sugar/glucose in the urine.  This results in increased urine volumes in all patients and a tripling […]

The post Third SGLT2 inhibitor to be marketed in Canada appeared first on BCDiabetes.

]]> https://www.bcdiabetes.ca/third-sglt2-inhibitor-in-canada/feed/ 2